All News


All series


All All News

A phase 2b clinical trial evaluating the efficacy and safety of an immunotherapy drug for patients with brain cancer has opened at Roswell Park Comprehensive Cancer Center in Buffalo, New York, with additional plans to be carried out at more than a dozen sites.

With newer treatments like Keytruda (pembrolizumab) approved for patients with cervical cancer, a younger patient population may be concerned about experiencing side effects that interrupt their lives — but if they occur, clinicians will be ready with a plan for management, says an expert from the Uniformed Services University of the Health Sciences.